Investigation of anticancer potential of hypophyllanthin and phyllanthin against breast cancer by \textit{in vitro} and \textit{in vivo} methods

Madhukiran Parvathaneni$^1$, Ganga Rao Battu$^1$, Alexander I Gray$^2$, Pitchaiah Gumalla$^1$

$^1$NAIP/ICAR Project, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530 003, India

$^2$Department of Pharmaceutical Sciences, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, Scotland, UK

\textbf{Objective:} To investigate the \textit{in vitro} and \textit{in vivo} anticancer activities of hypophyllanthin and phyllanthin isolated from \textit{Phyllanthus amarus} Schum & Thonn against breast cancer.

\textbf{Methods:} \textit{In vitro} anticancer activity was evaluated against two cell lines (MCF-7 and MDA–MB-231) using MTT assay. \textit{In vivo} anticancer activity was tested using Sprague-Dawley rats with N-methyl–N-nitrosourea group. \textit{In vitro} results demonstrated a dose-dependent inhibitory effect on cell growth with IC$_{50}$ values of (35.18±1.48) µg/mL (hypophyllanthin) and (32.51±0.95) µg/mL (phyllanthin) for MCF-7; (38.74±1.24) (hypophyllanthin) and (32.2±1.17) (phyllanthin) for MDA–MB–231 breast cancer cell lines. Tumor weights per group at doses of 5 and 10 mg/kg/day for hypophyllanthin (12.82 and 12.06 g) and phyllanthin (11.95 and 8.87 g) treated groups were significantly lower than untreated N-methyl–N-nitrosourea group.

\textbf{Conclusions:} Results of the present research work indicated that the isolated lignan compounds, hypophyllanthin and phyllanthin showed significant anticancer activities against breast cancer, \textit{in vitro} and \textit{in vivo}.

\textbf{KEYWORDS}

\textit{Phyllanthus amarus}, Hypophyllanthin, Phyllanthin, Breast cancer

\section{1. Introduction}

\textit{Phyllanthus amarus} Schum & Thonn (Euphorbiaceae) (\textit{P. amarus}) is locally well known as bhumi–amla and is officially listed in Indian herbal medicine system of Ayurveda. It is widely distributed in tropical areas of the world such as China, Java, Southern Florida, Bahamas, West Indies and Tropical America\cite{1}. The main active constituents of the herb are sterols\cite{1}, lignans\cite{2–3}, triterpenes, tannins, flavonoids\cite{4–8}, alkaloids and volatile oils\cite{9,10}. \textit{P. amarus} is highly valued in the treatment of liver ailments\cite{11}, kidney stones and cancer\cite{12–14}. It also acts as anti-viral, HIV replication and reverse transcriptase inhibitor agent\cite{15,16}.

However, most of the pharmacological activities were conducted on the complex extracts, and how each of these components contributed to the effects was not clearly understood, probably because of the commercially unavailable compounds. The lignans hypophyllanthin and phyllanthin of \textit{P. amarus} were found to have greater importance due to their potent bioactive nature against leukemia\cite{17}, hepatic diseases\cite{18,19}, free radical scavenging activity and inflammation\cite{19–21}.

Based on the structural chemistry of lignans (phytoestrogens) and their antioxidant properties (Figures 1 and 2), we hypothesized that isolated lignans hypophyllanthin and phyllanthin may have anticancer activities against breast cancer cell lines in \textit{in vitro} and \textit{in vivo} animal models. However, there are no such existing reports. To confirm this hypothesis, the inhibitory effect of hypophyllanthin and phyllanthin on the growth of breast cancer cells \textit{in vitro} and on the growth of N–methyl–N-nitrosourea (MNU) induced mammary cancer in Sprague Dawley (SD) rats \textit{in vivo} were...
investigated in this experimental study.

Hexane extract (25 g) was fractionated over a silica gel column (100.0x3.5 cm; Bonsil, India). Gradient elution was done in the following sequence, hexane (100, v/v), hexane:ethylacetate (95:5, v/v) and then hexane:ethylacetate (90:10, v/v). The fractions (Fr150–189) collected for hexane:ethylacetate (90:10, v/v) showed the presence of lignans on thin-layer chromatography with RF values of 0.36 (bluish green) and 0.45 (violet)\(^2\). These fractions were pooled together, concentrated and subjected to preparative HPLC separation for obtaining pure (>95\%) phyllanthin and hypophyllanthin.

2.4. **In vitro cytotoxicity assay**

The *in vitro* cytotoxicity assay of 1 and 2 was carried out on human estrogen receptor positive breast cancer cell lines (MCF-7) and human estrogen receptor negative breast cancer cell lines (MDA-MB-231) using MTT assay\[^{23,24}\]. Cells (15\( \times \)10\(^3\)) were plated in 100 \( \mu \)L of medium/well in 96-well microtiter plate. After 24 h incubation at 37 °C, hypophyllanthin and phyllanthin were added at different concentrations (10, 20, 40 and 80 \( \mu \)g/mL). Five wells were included in each compound concentration.

After 48 h of treatment, 10 \( \mu \)L of 5 mg/mL MTT reagent (Sigma, USA) was added to each well and cultivated at 4 °C for 1 h. The supernatant was then removed, 100 \( \mu \)L of dimethylsulfoxide was added and shaken at 960 r/min for 3 min. Absorbance was measured at 570 nm on a Tecan microtiter plate reader, (Switzerland). All experiments were performed in triplicate. The cytotoxicity effect of hypophyllanthin and phyllanthin on the growth of cancer cells was expressed as % cell growth inhibitions [(absorbance of control cells–absorbance of treated cells)/absorbance of control cells] \( \times \) 100.

2.5. **In vivo anticancer activity**

Female virgin SD rats were obtained from Mahaveer Enterprises (Hyderabad) at 35 d of age. Rats were housed at 4 per cage and maintained at (25±2) °C under 12 h dark/light cycle with access to standard diet (Nutrimix Std-1020, Nutravet Pvt. Ltd, Pune) and water *ad libitum*. Animals were experimented with prior approval from the Institutional Ethics Committee (Regd. No. 516/PO/c/01/CPCSEA), University College of Pharmaceutical Sciences, Andhra University. MNU (Sigma, USA) was dissolved in 0.9% NaCl containing 0.05% acetic acid (pH 5). Rats were given intraperitoneally 50 mg/kg of MNU on the 50th day\[^{25,26}\]. Animals were divided into different groups with eight animals in each group. Group I (intact control) received 0.9% NaCl i.p., adjusted to pH 5.0 with acetic acid. Groups II–VII were induced with MNU and after 85 d (all rats developed at least one tumor), animals were treated with tamoxifen at 2 mg/kg/day (Fresenius Oncology Ltd., India) and isolated compounds, hypophyllanthin and phyllanthin (5 mg/kg and 10 mg/kg in 1% sodium carboxymethyl cellulose orally by gavage once per day) for 4 weeks (from 96th to 113th day). Animals in intact control group and untreated MNU group were given vehicle (sodium carboxymethyl cellulose suspension) according to experimental protocol.

After completion of treatment, blood was collected from retro orbital puncture and the hematological parameters like red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and platelets (PLTs) were estimated by fully-auto-hematology analyzer (Erba Scientific, India\[^{27}\]). At the end of the
experiment all animals were sacrificed, tumors were excised for the measurement of different tumor parameters like tumor incidence (number of animals with tumors), tumor multiplicity (number of tumors per rat observed in different treated groups) and tumor weight (tumor weight per rat in each group)\(^{(27,28)}\). Tumors were fixed in 10% buffered formalin. Paraffin sections (5 μm thickness) of the excised tissue were made using microtome and were stained with haematoxylin and eosin for histopathological evaluation. The breast cancer disease pathology and histological types were studied.

2.6. Statistical analysis

The results of the in vitro experiments were expressed as mean ±SEM and were statistically analyzed using Dunnett’s multiple comparison test. The IC\(_50\) values were obtained from nonlinear regression analysis by using Graphpad prism-5 software. In the in vitro experiments the difference in % tumor incidence, tumor multiplicity per rat and tumor weight per group were statistically evaluated by One-way analysis of variance (ANOVA), followed by Dunnett’s test. Values of \(P<0.05\) were considered to be significant.

3. Results

3.1. In vitro cytotoxicity assay

Figures 3 and 4 reveal the dose-dependent inhibitory effect exhibited by hypophyllanthin and phyllanthin on in vivo growth of MCF-7 and MDA-MB-231 breast cancer cells. Furthermore the study demonstrated that the anticancer activity of phyllanthin is more potent than hypophyllanthin as detailed in Table 1.

![Figure 3](image-url)  
**Figure 3.** Percentage cell growth inhibition of MCF-7 cells treated with hypophyllanthin and phyllanthin (mean±SEM, n=3).

![Figure 4](image-url)  
**Figure 4.** Percentage cell growth inhibition of MDA-MB-231 treated with hypophyllanthin and phyllanthin (mean±SEM, n=3).

| Compounds | MCF-7 | MDA-MB-231 |
|-----------|-------|------------|
| Hypophyllanthin | 90.17±1.62 | 99.56±2.85 |
| Phyllanthin | 92.27±2.84 | 94.14±3.14 |

3.2. In vivo anticancer activity

Oral administration to SD rats bearing MNU induced mammary cancer with hypophyllanthin and phyllanthin at doses of 5 mg/kg and 10 mg/kg significantly decreased the mammary cancer. The incidence rate in untreated MNU group was found to be 85.7%. Mammary tumors first appeared after 12 weeks of the MNU injection, six rats developed at least one tumor out of remaining seven rats in the untreated MNU group (one rat out of eight died after four days of MNU injection). Table 2 reflects the tumor incidence, tumor multiplicity and tumor weights of different treatment groups. Phyllanthin at a dose of 10 mg/kg showed highest reduction of mammary tumor incidence of 31.5% next to tamoxifen treated group (25%). There was nearly 54.2% reduction in the incidence rates of phyllanthin (10 mg/kg) treated group when compared to the untreated MNU group and this better explains the anticancer potential of phyllanthin.

![Table 1](table-url)  
**Table 1**  
Percentage cell growth inhibition (\% CGI) and IC\(_{50}\) values of hypophyllanthin and phyllanthin.

| Compounds        | MCF-7 IC\(_{50}\) (μg/mL) | MDA-MB-231 IC\(_{50}\) (μg/mL) |
|------------------|---------------------------|-------------------------------|
| Hypophyllanthin  | 2.67±0.21                 | 1.38±0.03                     |
| Phyllanthin      | 2.50±0.16                 | 1.25±0.04                     |

The weight of grossly detectable mammary tumors in untreated MNU group was 35.85 g ranging from 0.06 g to 4.9 g per tumor. The mean tumor weight per rat in untreated MNU group was 5.12±0.26 g. The weight of total mammary tumors per group (total tumor mass) ranged from 4.67 g to 35.85 g. The majority of rats (65%) had a total tumor mass lower than 4.50 g per rat. Tamoxifen treated group showed significant \(P<0.01\) decrease of total tumor weight (4.67 g). Furthermore the groups treated with hypophyllanthin and phyllanthin showed significant \(P<0.001\) decrease in tumor weight. The total tumor weight of phyllanthin treated groups was decreased from 11.95 g to 8.87 g with increase in dose from 5 mg/kg to 10 mg/kg whereas no such remarkable change was observed with increase in hypophyllanthin dose.

Table 3 reflects the hematological analysis data of tumor bearing rats treated with hypophyllanthin and phyllanthin. Untreated MNU group showed significant decrease \(P<0.05\) in number of RBC, PLTs and Hb indicating a tendency of anemia, whereas concomitant increase in WBC was observed indicating the diseased state. Tamoxifen (standard drug for breast cancer treatment) treated group showed significant \(P<0.05\) reversal of
all hematological parameters to normal levels. Upon treatment with hypophyllanthin and phyllanthin all hematological parameters which were altered by induction of mammary cancer were considerably restored.

**Table 3**

Hematological analysis of tumor bearing rats treated with hypophyllanthin and phyllanthin.

| Treatment/group                  | WBCs ($10^3/µL$) | RBCs ($10^6/µL$) | Hb (g/L) | PLTs ($10^3/µL$) |
|----------------------------------|------------------|------------------|-----------|-----------------|
| Control (DV oral)                | 6.52±1.27        | 7.17±1.22        | 13.81±2.08| 660.07±31.61    |
| MNU                             | 12.62±2.65       | 6.18±2.21        | 11.22±2.35| 486.24±28.11    |
| MNU+tamoxifen (2mg/kg)          | 7.51±1.34        | 6.97±1.17        | 13.25±1.12| 571.70±21.25    |
| MNU+(1) (5 mg/kg)               | 9.25±0.69        | 6.78±1.74        | 11.95±2.29| 522.41±83.24    |
| MNU+(1) (10 mg/kg)              | 8.74±1.35        | 7.94±1.67        | 12.48±3.51| 536.08±93.97    |
| MNU+(2) (5 mg/kg)               | 8.95±1.67        | 6.75±1.64        | 12.25±2.46| 517.58±17.50    |
| MNU+(2) (10 mg/kg)              | 8.63±1.34        | 6.82±1.71        | 12.72±2.77| 547.58±25.84    |

*a*: $P<0.001$; *b*: $P<0.01$; *c*: $P<0.05$ compared with control. Results are given as mean±SEM.

Table 3: Hypophyllanthin and phyllanthin treated groups (H&E, ×140).

Figure 5 clearly depicts the MNU induced mammary tumor in untreated rat. Histology of normal mammary gland (Figure 6A) shows the presence of lobules (L) with numerous acini and clear basement membrane (BM). Photomicrographs (Figures 6B–F) of mammary tissue of untreated MNU group clearly show marked proliferation of stroma (SP) resulted due to stromal reaction with carcinogen. Figure 6B depicts the distribution of congested blood vessels (BV) in stroma. Figure 6C reveals complete tumor tissue necrosis (NC) owing to increased tumor size followed by congestion of blood vessels and insufficient blood supply to the tumor tissue. Figure 6D demonstrates a well circumscribed tumor composed of closely packed tubules (T), giving rise to 'back to back fashion'. The tubules are lined by inner epithelial cells and basal myoepithelial cells. In between the tubules, stroma (S) was very scanty with mixed mononuclear cell infiltrate and prominent mast (M) cells.

Figure 6E shows the presence of intraluminal secretions (SE) of tubules (T). The epithelial component of tumors was organized into acinar structures but the growth pattern was variable from one region to another in the same tumor, with areas of typical well differentiated adenocarcinoma showing papillary and cribriform patterns. Figure 6F clearly demonstrates the formation of well–defined capsule (CP) by fibrous collagenous tissue in between adipose (AD) and cancerous tissues (CT), which is a characteristic feature of breast cancer. Upon comparison with untreated MNU group, the animals treated with hypophyllanthin and phyllanthin showed small sized tumors. Histology of phyllanthin treated rat tumors showed reduced necrosis (NC) (Figure 6H) when compared with hypophyllanthin treated rat tumors which showed moderate number of necrotic cells (NC) (Figure 6G). This reduced necrosis in Figure 6H was due to potent inhibition of mammary tumor growth with significant decrease in tumor multiplicity and tumor weight associated with phyllanthin treatment.
4. Discussion

Breast cancer is one of the main life-threatening diseases[29]. Though different anticancer drugs were present in the market because of their serious adverse effects there is still need to identify potent anticancer molecules from natural origin. Herbal medicine has been regarded as one of the most visible fields for cancer chemoprevention and it constitutes the main source of effective new anticancer agents[30,31]. Plant lignans were found to have potent anticancer activity against breast cancer.

Aqueous and alcoholic extracts of *P. amarus* showed cytotoxicity against lung cancer (A549), breast cancer (MCF-7 and MDA-MB-435) and leukemia (K-562; Lucena-1) cell lines. Cytotoxic activity against cancer lines has been reported for several members of lignans. Hypophyllanthin and phyllanthin exhibited *in vitro* cytotoxic activity against leukemia cells (K-562) and they also showed *in vivo* anticancer activity against Ehrlich ascites carcinoma (EAC) in Swiss albino mice[1,17]. This is the first study reporting the cytotoxic activity of hypophyllanthin and phyllanthin against MCF-7 and MDA-MB-231 breast cancer cell lines.

In the present research, *in vivo* anticancer activity of hypophyllanthin and phyllanthin against MNU induced mammary cancer in SD rats was reported for the first time. The present *in vitro* and *in vivo* anticancer activities exhibited by hypophyllanthin and phyllanthin might be allied with different mechanisms like direct free radical scavenging activity[19], inhibition of cytochrome P450 enzymes (Phase-I enzymes) which can cause specific mutations leading to carcinogenesis, and interference with estradiol biosynthesis by inhibition of key steroid enzymes like steroid dehydrogenase and aromatase which are previously reported for anticancer activity of lignans[13,32].

In conclusion, for the first time, the anticancer activities of hypophyllanthin and phyllanthin against human breast cancer lines *in vitro* and MNU induced mammary carcinoma *in vivo* were reported in this experimental study. The results demonstrated that hypophyllanthin and phyllanthin exhibited a strong inhibitory effect on the growth of MCF-7 and MDA-MB-231 human breast cancer cells *in vitro* and inhibited growth of mammary carcinoma *in vivo*. The results of this experimental study suggested that hypophyllanthin and phyllanthin would be useful as anticancer agents. The use of these lignans as applied therapeutics needs to be further investigated.

**Conflict of interest statement**

We declare that we have no conflict of interest.

**Acknowledgements**

This work was funded by National Agricultural Innovation Project and Indian Council for Agricultural Research, Government of India (NAIP/ICAR Project; Grant No. C4/40043101). The authors gratefully acknowledge the assistance from Prof. A. Annapurna, Department of Pharmacology and Dr. Balaji Path, Pathologist, King George Hospital, Visakhapatnam in carrying out the anticancer activity.

**Comments**

**Background**

Cancer disease is increasing day by day. Though several anticancer drugs are being used in the treatment, because of their side effects and chemoresistance of cancer cells to those drugs there is need to develop new therapies. The manuscript describes screening of isolated compounds, hypophyllanthin and phyllanthin against two different breast cancer cell lines (*in vitro*) using MTT assay and MNU induced mammary cancer model (*in vivo*) in rats. This manuscript will be helpful for developing new therapies in the field of breast cancer research.

**Research frontiers**

The author reported the efficacy of hypophyllanthin and phyllanthin for the inhibition of growth of human breast cancer cell lines (MCF-7 and MDA-MB-231) and inhibition of the mammary tumor growth in rats. Among the tested compounds, phyllanthin showed significant inhibition of both cell lines in *in vitro* studies and also significantly inhibited the growth of mammary tumors which was comparable to that of marketed drug tamoxifen.

**Related reports**

The natural products and isolated compounds are screened by using MTT assay (Mosmann T, 1983 and Muhammad Zia et al., 2013). The screening methodology was well defined in the manuscript and the results were presented in a good way. The results were further supported by previous anticancer reports on four plant species of *Phyllanthus* (Lee SH et al., 2011 and Sureban SM et al., 2006).

The *in vivo* anticancer activity is performed for the first time and is more innovative.

**Innovations & breakthroughs**

The isolated lignans are having their structure related to gonadal hormones and by basing on this hypothesis the authors for the first time evaluated and reported the efficacy of hypophyllanthin and phyllanthin against breast cancer by *in vitro* and *in vivo* methods.

**Applications**

This study is applicable for developing new therapeutic agents used for breast cancer therapy.

**Peer review**

The manuscript is well documented and the results are discussed in a good way with suitable references. This research will be helpful for exploring highly potent new anticancer molecules for better therapy.
References

[1] Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus ethnopharmacological uses, phytochemistry and pharmacology: a review. J Ethnopharmacol 2011; 138: 286–313.

[2] Huang RL, Huang YL, Ou JC, Chen CC, Hsu FL, Chang C. Screening of 25 compounds isolated from Phyllanthus species for anti-human hepatitis B virus in vitro. Phytother Res 2003; 17: 449–453.

[3] Kassuya CA, Leite DF, de Melo LV, Rehder VL, Calixto JB. Anti-inflammatory properties of extracts, fractions and lignans isolated from Phyllanthus amarus. Planta Med 2005; 71: 721–726.

[4] Singh M, Tiwari N, Shanker K, Verma RK, Gupta MM. Two new lignans from Phyllanthus amarus. J Asian Nat Prod Res 2009; 11: 562–568.

[5] Srivastava V, Singh M, Malasoni R, Shanker K, Verma RK, Gupta MM, et al. Separation and quantification of lignans in Phyllanthus species by a simple chiral densitometric method. J Sep Sci 2008; 31: 47–55.

[6] Foo LY. Amarulone a novel cyclic hydrolyzable tannin from Phyllanthus amarus. Nat Prod Lett 1993; 3: 45–52.

[7] Foo LY. Amarisi acid and related ellagitannins from Phyllanthus amarus. Phytochemistry 1995; 39: 217–224.

[8] Maciel MAM, Cunha A, Dantas FTNC, Kaiser CR. NMR property of sediment actinomycetes against MCF-7 and MDA-MB-231 cell lines. Asian Pac J Trop Biomed 2012; 2: 92–96.

[9] Gotob T, Yamada K, Ito A, Yin H, Kataoka T, Doji K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. In J Cancer Res 1998; 89: 487–495.

[10] McCormick DL, Becci PJ, Moon RC. Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride–divinyl ether copolymer (MVE-2). Carcinogenesis 1982; 3: 1473–1476.

[11] Jagatheesh K, Arumugam V, Elangovan N, Pavan Kumar P. Evaluation of the anti-tumor and antioxidant activity of Amorphophallus paeonifolius on DMBA induced mammary carcinoma. Int J Cancer Pharm Biol 2012; 3: 291–295.

[12] Angelopoulos N, Barbounis V, Livadas S, Kalsas D, Tolis G. Effects of estrogen deprivation due to breast cancer treatment. Endocr Relat Cancer 2004; 11: 523–535.

[13] Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, et al. Modulations of the Bcl–2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J Agric Food Chem 2004; 52: 1715–1719.

[14] Kritika R, Mohankumar R, Verma RJ, Srivastava PS, Mohamad H, Gunasekaran P, et al. Isolation, characterization and antioxidative effect of phyllanthin against CCL–induced toxicity in HepG2 cell line. Chem Biol Interact 2009; 181: 351–358.

[15] Rao BG, Kiran PM, Kumar JR. In vitro antioxidant activity of different extracts and isolated lignans of Phyllanthus amarus Schum. & Thonn. aerial parts. Int J Pharm Bio Sci 2013; 4: 803–808.

[16] Anjanyeluyu AR, Rao JK, Row LR, Subrahmanyan C. Crystalline constituents of Euphorbiaceae–XII: Isolation and structural elucidation of three new lignans from the leaves of Phyllanthus niruri. Tetrahedron 1973; 2: 1291–1298.

[17] Waheed A, Bibi Y, Nisa S, Chaudhary FM, Sahreen S, Zia M. Inhibition of human breast and colorectal cancer cells by Viburum foetens L. extracts in vitro. Asian Pac J Trop Dis 2013; 3: 32–36.

[18] Ravi Kumar S, Fredimoses M, Gnanadesigan M. Anticancer property of sediment actinomycetes against MCF–7 and MDA–MB–231 cell lines. Asian Pac J Trop Biomed 2012; 2: 92–96.

[19] Gotob T, Yamada K, Ito A, Yin H, Kataoka T, Doji K. Chemoprevention of N-nitroso-N-methylurea–induced mammary cancer by miso and tamoxifen, alone and in combination. In J Cancer Res 1998; 89: 487–495.

[20] McCormick DL, Becci PJ, Moon RC. Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride–divinyl ether copolymer (MVE-2). Carcinogenesis 1982; 3: 1473–1476.

[21] Jagatheesh K, Arumugam V, Elangovan N, Pavan Kumar P. Evaluation of the anti-tumor and antioxidant activity of Amorphophallus paeonifolius on DMBA induced mammary carcinoma. Int J Chem Pharm Sci 2010; 1: 40–49.

[22] Roomi MW, Roomi NW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of N–methyl–N–nitrosourea induced mammary tumors in Sprague–Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. Breast Cancer Res 2005; 7: 291–295.

[23] Angelopoulos N, Barbounis V, Livadas S, Kalsas D, Tolis G. Effects of estrogen deprivation due to breast cancer treatment. Endocr Relat Cancer 2004; 11: 523–535.